Horizons of nanotechnology applications in female specific cancers

Balney Rajitha, Rama Rao Malla, Ramakrishna Vadde, Prameswari Kasa, Ganji Lakshmi Vara Prasad, Batoul Farran, Seema Kumari, Eluri Pavitra, Mohammad Amjad Kamal, Ganji Seeta Rama Raju, Sujatha Peela, Ganji Purnachandra Nagaraju

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations

Abstract

Female-specific cancers are the most common cancers in women worldwide. Early detection methods remain unavailable for most of these cancers, signifying that most of them are diagnosed at later stages. Furthermore, current treatment options for most female-specific cancers are surgery, radiation and chemotherapy. Although important milestones in molecularly targeted approaches have been achieved lately, current therapeutic strategies for female-specific cancers remain limited, ineffective and plagued by the emergence of chemoresistance, which aggravates prognosis. Recently, the application of nanotechnology to the medical field has allowed the development of novel nano-based approaches for the management and treatment of cancers, including female-specific cancers. These approaches promise to improve patient survival rates by reducing side effects, enabling selective delivery of drugs to tumor tissues and enhancing the uptake of therapeutic compounds, thus increasing anti-tumor activity. In this review, we focus on the application of nano-based technologies to the design of novel and innovative diagnostic and therapeutic strategies in the context of female-specific cancers, highlighting their potential uses and limitations.

Original languageEnglish (US)
Pages (from-to)376-390
Number of pages15
JournalSeminars in Cancer Biology
Volume69
DOIs
StatePublished - Feb 2021
Externally publishedYes

Keywords

  • Breast cancer
  • Cervical cancer
  • Female specific cancers
  • Nanotechnology
  • Ovarian cancer

ASJC Scopus subject areas

  • Cancer Research

Fingerprint

Dive into the research topics of 'Horizons of nanotechnology applications in female specific cancers'. Together they form a unique fingerprint.

Cite this